ES2754264T3 - Análogo de piridin[1,2-a]pirimidona utilizado como inhibidor de PI3K - Google Patents
Análogo de piridin[1,2-a]pirimidona utilizado como inhibidor de PI3K Download PDFInfo
- Publication number
- ES2754264T3 ES2754264T3 ES15810067T ES15810067T ES2754264T3 ES 2754264 T3 ES2754264 T3 ES 2754264T3 ES 15810067 T ES15810067 T ES 15810067T ES 15810067 T ES15810067 T ES 15810067T ES 2754264 T3 ES2754264 T3 ES 2754264T3
- Authority
- ES
- Spain
- Prior art keywords
- alkyl
- group
- cyclohydrocarbyl
- heterocyclohydrocarbyl
- heteroalkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- QRKOBESRHNBAQK-UHFFFAOYSA-N CN(C)CCOc(c(NS(c(c(F)c1)ccc1F)(=O)=O)c1)ncc1C(C=CC1=NC=C2Cl)=CN1C2=O Chemical compound CN(C)CCOc(c(NS(c(c(F)c1)ccc1F)(=O)=O)c1)ncc1C(C=CC1=NC=C2Cl)=CN1C2=O QRKOBESRHNBAQK-UHFFFAOYSA-N 0.000 description 1
- HDXVTQVEQTVENE-UHFFFAOYSA-N CNCCOc(c(NS(c(c(F)c1)ccc1F)(=O)=O)c1)ncc1C(C=CC1=NC=C2Cl)=CN1C2=O Chemical compound CNCCOc(c(NS(c(c(F)c1)ccc1F)(=O)=O)c1)ncc1C(C=CC1=NC=C2Cl)=CN1C2=O HDXVTQVEQTVENE-UHFFFAOYSA-N 0.000 description 1
- RPSTYXAPROLDNX-UHFFFAOYSA-N COc(c(NC(Nc(ccc(F)c1)c1Cl)=O)c1)ncc1C(C=CC1=NC=C2OCCN3CCOCC3)=CN1C2=O Chemical compound COc(c(NC(Nc(ccc(F)c1)c1Cl)=O)c1)ncc1C(C=CC1=NC=C2OCCN3CCOCC3)=CN1C2=O RPSTYXAPROLDNX-UHFFFAOYSA-N 0.000 description 1
- JDFFQWXREVXEFQ-UHFFFAOYSA-N COc(c(NC(c(c(Cl)c1)ccc1F)=O)c1)ncc1C(C=CC1=NC=C2OCCN3CCOCC3)=CN1C2=O Chemical compound COc(c(NC(c(c(Cl)c1)ccc1F)=O)c1)ncc1C(C=CC1=NC=C2OCCN3CCOCC3)=CN1C2=O JDFFQWXREVXEFQ-UHFFFAOYSA-N 0.000 description 1
- KYULFPRHBKJVCA-UHFFFAOYSA-N COc(c(NS(c(ccc(F)c1)c1Cl)(=O)=O)c1)ncc1C(C=CC1=NC(OCCN2CCOCC2)=C2)=CN1C2=O Chemical compound COc(c(NS(c(ccc(F)c1)c1Cl)(=O)=O)c1)ncc1C(C=CC1=NC(OCCN2CCOCC2)=C2)=CN1C2=O KYULFPRHBKJVCA-UHFFFAOYSA-N 0.000 description 1
- LCRFGZIUACFCTI-UHFFFAOYSA-N Cc(nc(C)[s]1)c1S(Nc1cc(C(C=CC2=NC=C3CN(C)C)=CN2C3=O)cnc1OC)(=O)=O Chemical compound Cc(nc(C)[s]1)c1S(Nc1cc(C(C=CC2=NC=C3CN(C)C)=CN2C3=O)cnc1OC)(=O)=O LCRFGZIUACFCTI-UHFFFAOYSA-N 0.000 description 1
- PSQHTFAFDLVSMZ-UHFFFAOYSA-N Cc(nc(C)[s]1)c1S(Nc1cc(C(C=CC2=NC=C3CN4CCOCC4)=CN2C3=O)cnc1OC)(=O)=O Chemical compound Cc(nc(C)[s]1)c1S(Nc1cc(C(C=CC2=NC=C3CN4CCOCC4)=CN2C3=O)cnc1OC)(=O)=O PSQHTFAFDLVSMZ-UHFFFAOYSA-N 0.000 description 1
- LEQKWADCYQGLKQ-UHFFFAOYSA-N Cc1c(C(Nc(cc(cn2)C(C=CC3=NC=C4OCCN5CCOCC5)=CN3C4=O)c2OC)=O)[s]c(C)n1 Chemical compound Cc1c(C(Nc(cc(cn2)C(C=CC3=NC=C4OCCN5CCOCC5)=CN3C4=O)c2OC)=O)[s]c(C)n1 LEQKWADCYQGLKQ-UHFFFAOYSA-N 0.000 description 1
- QYSPXCPOYOVSAP-UHFFFAOYSA-N Cc1c(NC(Nc2cc(C(C=CC3=NC=C4OCCN5CCOCC5)=CN3C4=O)cnc2OC)=O)[s]c(C)n1 Chemical compound Cc1c(NC(Nc2cc(C(C=CC3=NC=C4OCCN5CCOCC5)=CN3C4=O)cnc2OC)=O)[s]c(C)n1 QYSPXCPOYOVSAP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Pyridine Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410271282.9A CN105461711B (zh) | 2014-06-17 | 2014-06-17 | 作为PI3K抑制剂的吡啶并[1,2-a]嘧啶酮类似物 |
| CN201510324348 | 2015-06-12 | ||
| PCT/CN2015/081518 WO2015192760A1 (zh) | 2014-06-17 | 2015-06-16 | 作为pi3k抑制剂的吡啶并［1，2-a］嘧啶酮类似物 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2754264T3 true ES2754264T3 (es) | 2020-04-16 |
Family
ID=54934872
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES15810067T Active ES2754264T3 (es) | 2014-06-17 | 2015-06-16 | Análogo de piridin[1,2-a]pirimidona utilizado como inhibidor de PI3K |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US9856256B2 (enExample) |
| EP (1) | EP3159341B8 (enExample) |
| JP (1) | JP6680774B2 (enExample) |
| KR (1) | KR102495840B1 (enExample) |
| CN (1) | CN106470992B (enExample) |
| AU (1) | AU2015276699B2 (enExample) |
| CA (1) | CA2951971C (enExample) |
| EA (1) | EA032642B1 (enExample) |
| ES (1) | ES2754264T3 (enExample) |
| TW (1) | TWI628180B (enExample) |
| WO (1) | WO2015192760A1 (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10479789B2 (en) * | 2015-12-16 | 2019-11-19 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Pyrido[1,2-A]pyrimidone analog, crystal form thereof, intermediate thereof and preparation method therefor |
| CN110386932A (zh) | 2018-04-20 | 2019-10-29 | 艾科思莱德制药公司 | 用于抗肿瘤疗法中的双重atm和dna-pk抑制剂 |
| CN113316575B (zh) * | 2019-01-24 | 2022-03-18 | 江苏奥赛康药业有限公司 | 作为TGF-βR1激酶抑制剂的5-(4-吡啶氧基)吡唑类化合物 |
| CN115151540A (zh) | 2019-12-02 | 2022-10-04 | 风暴治疗有限公司 | 作为mettl3抑制剂的多杂环化合物 |
| EP4095137A4 (en) * | 2020-02-10 | 2024-03-13 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | USE OF A PYRIDO[1,2-A]PYRIMIDINONE COMPOUND FOR THE TREATMENT OF LYMPHOMAS |
| US20230119759A1 (en) | 2020-03-10 | 2023-04-20 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Pharmaceutical combination comprising pyridino[1,2-a]pyrimidinone compound |
| CN116323609B (zh) * | 2020-09-15 | 2026-02-24 | 正大天晴药业集团股份有限公司 | 吡啶并[1,2-a]嘧啶酮化合物的治疗外周T细胞淋巴瘤的用途 |
| CN116761608A (zh) * | 2020-12-08 | 2023-09-15 | 正大天晴药业集团股份有限公司 | 吡啶并[1,2-a]嘧啶酮化合物的治疗妇科肿瘤的用途 |
| CN118510518A (zh) * | 2022-03-09 | 2024-08-16 | 正大天晴药业集团股份有限公司 | 包括吡啶并[1,2-a]嘧啶酮化合物和EGFR抑制剂的药物组合 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1678180B1 (en) * | 2003-10-10 | 2007-08-08 | Pfizer Products Incorporated | Substituted 2h-[1,2,4]triazolo 4,3-a pyrazines as gsk-3 inhibitors |
| EP2038272B8 (en) * | 2006-06-30 | 2013-10-23 | Sunesis Pharmaceuticals, Inc. | Pyridinonyl pdk1 inhibitors |
| JP2011500823A (ja) * | 2007-10-22 | 2011-01-06 | グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー | Ｐｉ３キナーゼ阻害物質としてのピリドスルホンアミド誘導体 |
| JP5599783B2 (ja) * | 2008-05-30 | 2014-10-01 | アムジエン・インコーポレーテツド | Ｐｉ３キナーゼの阻害薬 |
| WO2012003392A1 (en) * | 2010-07-02 | 2012-01-05 | Gilead Sciences, Inc. | Fused heterocyclic compounds as ion channel modulators |
| WO2012037108A1 (en) * | 2010-09-13 | 2012-03-22 | Glaxosmithkline Llc | Aminoquinoline derivatives as antiviral agents |
| JP5820080B2 (ja) * | 2011-11-17 | 2015-11-24 | 山▲東▼▲軒▼竹医▲葯▼科技有限公司 | 三環系ＰＩ３Ｋ及び／又はｍＴＯＲ抑制剤 |
| CN103539777B (zh) * | 2012-07-13 | 2016-03-02 | 广东东阳光药业有限公司 | Pi3激酶调节剂及其使用方法和用途 |
| WO2014022128A1 (en) * | 2012-07-29 | 2014-02-06 | Calitor Sciences, Llc | Pi3 kinase modulators and methods of use |
| TW201443037A (zh) * | 2013-01-09 | 2014-11-16 | Gilead Sciences Inc | 治療用化合物 |
| BR112016029825B1 (pt) * | 2014-06-17 | 2020-10-27 | Cisen Pharmaceutical Co., Ltd. | composto |
-
2015
- 2015-06-16 AU AU2015276699A patent/AU2015276699B2/en active Active
- 2015-06-16 US US15/319,726 patent/US9856256B2/en active Active
- 2015-06-16 EA EA201790016A patent/EA032642B1/ru not_active IP Right Cessation
- 2015-06-16 KR KR1020177000523A patent/KR102495840B1/ko active Active
- 2015-06-16 WO PCT/CN2015/081518 patent/WO2015192760A1/zh not_active Ceased
- 2015-06-16 ES ES15810067T patent/ES2754264T3/es active Active
- 2015-06-16 CA CA2951971A patent/CA2951971C/en active Active
- 2015-06-16 JP JP2017518397A patent/JP6680774B2/ja active Active
- 2015-06-16 EP EP15810067.7A patent/EP3159341B8/en active Active
- 2015-06-16 CN CN201580027396.1A patent/CN106470992B/zh active Active
- 2015-06-17 TW TW104119646A patent/TWI628180B/zh active
Also Published As
| Publication number | Publication date |
|---|---|
| EA201790016A1 (ru) | 2017-06-30 |
| TW201625612A (zh) | 2016-07-16 |
| CA2951971C (en) | 2024-09-10 |
| EP3159341B8 (en) | 2020-01-08 |
| KR102495840B1 (ko) | 2023-02-03 |
| JP6680774B2 (ja) | 2020-04-15 |
| AU2015276699A1 (en) | 2017-01-19 |
| AU2015276699B2 (en) | 2019-10-10 |
| US9856256B2 (en) | 2018-01-02 |
| JP2017519821A (ja) | 2017-07-20 |
| US20170137420A1 (en) | 2017-05-18 |
| CN106470992B (zh) | 2018-11-06 |
| EP3159341A4 (en) | 2018-05-16 |
| EA032642B1 (ru) | 2019-06-28 |
| TWI628180B (zh) | 2018-07-01 |
| CN106470992A (zh) | 2017-03-01 |
| CA2951971A1 (en) | 2015-12-23 |
| EP3159341B1 (en) | 2019-08-21 |
| WO2015192760A1 (zh) | 2015-12-23 |
| EP3159341A1 (en) | 2017-04-26 |
| KR20170016465A (ko) | 2017-02-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20150218A1 (es) | Nuevos derivados fosfatos, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen | |
| EA201650029A1 (ru) | Пиразолопиридины и пиразолопиримидины | |
| JO3377B1 (ar) | مشتقات بيريدينيل وبيريدينيل مندمج | |
| GT201300291A (es) | Derivados de piridin-2(1h)-ona útiles como medicamentos para el tratamiento de trastornos mieloproliferativos, rechazo de trasplantes, enfermedades mediadas por el sistema inmune y enfermedades inflamatorias. | |
| AR107127A1 (es) | Indazoles sustituidos, procedimientos para su preparación, preparaciones farmacéuticas que los contienen, así como su uso para la preparación de medicamentos | |
| AR101177A1 (es) | Inhibidores de la syk | |
| MX373042B (es) | Moleculas para administracion a celulas cancerosas mutantes ros1. | |
| CO6531469A2 (es) | Derivados de purina o deazapurina utiles para el tratamiento de (entre otros) infecciones virales | |
| DOP2013000243A (es) | Inhibidores sustituidos de acetil-coa carboxilasa | |
| AR064454A1 (es) | Derivados de pirazol con efecto inhibitorio de fgfr, metodos para su sintesis, composicion farmaceutica que los comprende, un proceso para la preparacion de la misma y su uso en la fabricacion de un medicamento para el tratamiento del cancer. | |
| MX2017006483A (es) | Compuestos aminopirazina con propiedades antagonistas a2a. | |
| PE20171307A1 (es) | Compuestos de triazolopirimidina y usos de los mismos | |
| BR112016015838A8 (pt) | compostos heterocíclicos aromáticos, composição farmacêutica compreendendo os referidos compostos e produto de combinação | |
| MX2020007023A (es) | Analogos detiadiazol y metodos para el tratamiento de afecciones relacionadas con la deficiencia del gen de supervivencia de las neuronas motoras (smn). | |
| NZ718430A (en) | Heterocyclic compounds and uses thereof | |
| PE20151592A1 (es) | Formulacion de liberacion sostenida de mosapride que proporciona efectos farmacologicos y clinicos con administracion una vez al dia | |
| AR103934A1 (es) | Derivados de benzimidazoles como inhibidores de bromodominio | |
| PE20151655A1 (es) | Aglomerados respirables de particulas de vehiculo porosas y farmaco micronizado | |
| AR051753A1 (es) | Metodos para preparar compuestos de indazol | |
| CY1124058T1 (el) | Διαδικασια κρυσταλλωσης των παραγωγων αριπιπραζολης σε φαρμακοτεχνικες μορφες παρατεταμενης απελευθερωσης για τη θεραπευτικη αντιμετωπιση της σχιζοφρενειας | |
| CO6420344A2 (es) | Derivados de triazolopiridina como inhibidores de proteínas cinasas activadas por mitogeno p38 (map) | |
| ECSP16090804A (es) | Compuestos heteroaromáticos y su uso como ligandos de dopamina d1 | |
| CR20190106A (es) | Compuestos derivados de imidazol y su uso en el tratamiento de enfermedades autoinmunitarios o inflamatorios o cánceres | |
| BR112019008263A2 (pt) | formulação lipossomal para uso no tratamento de câncer | |
| DOP2016000289A (es) | Compuestos heteroaromáticos y su uso como ligandos de dopamina d1 |